214 related articles for article (PubMed ID: 34409593)
1. COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany).
El-Battrawy I; Nuñez-Gil IJ; Abumayyaleh M; Estrada V; Manuel Becerra-Muñoz V; Uribarri A; Fernández-Rozas I; Feltes G; Arroyo-Espliguero R; Trabattoni D; López-País J; Pepe M; Romero R; Castro-Mejía AF; Cerrato E; Capel Astrua T; D'Ascenzo F; Fabregat-Andres O; Signes-Costa J; Marín F; Buonsenso D; Bardají A; Jesús Tellez M; Fernández-Ortiz A; Macaya C; Akin I
Eur J Clin Invest; 2021 Nov; 51(11):e13582. PubMed ID: 34409593
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
3. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Dos Santos TM; Mazza L; Feldman A; D'Andréa Saba Arruda G; de Albuquerque DC; Camiletti AS; de Sousa AS; de Paula TC; Giusti KGD; Domiciano RAM; Noya-Rabelo MM; Hamilton AM; Loures VA; Dionísio RM; Furquim TAB; De Luca FA; Dos Santos Sousa ÍB; Bandeira BS; Zukowski CN; de Oliveira RGG; Ribeiro NB; de Moraes JL; Petriz JLF; Pimentel AM; Miranda JS; de Jesus Abufaiad BE; Gibson CM; Granger CB; Alexander JH; de Souza OF;
JAMA; 2021 Jan; 325(3):254-264. PubMed ID: 33464336
[TBL] [Abstract][Full Text] [Related]
4. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
de Abajo FJ; Rodríguez-Miguel A; Rodríguez-Martín S; Lerma V; García-Lledó A;
BMC Med; 2021 May; 19(1):118. PubMed ID: 33980231
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry.
Núñez-Gil IJ; Olier I; Feltes G; Viana-Llamas MC; Maroun-Eid C; Romero R; Fernández-Rozas I; Uribarri A; Becerra-Muñoz VM; Alfonso-Rodriguez E; García-Aguado M; Elola J; Castro-Mejía A; Pepe M; Garcia-Prieto JF; Gonzalez A; Ugo F; Cerrato E; Bondia E; Raposeiras-Roubin S; Mendez JLJ; Espejo C; López-Masjuan Á; Marin F; López-Pais J; Abumayyaleh M; Corbi-Pascual M; Liebetrau C; Ramakrishna H; Estrada V; Macaya C; Fernandez-Ortiz A;
Am Heart J; 2021 Jul; 237():104-115. PubMed ID: 33845032
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
Rizk JG; Wenziger C; Tran D; Hashemi L; Moradi H; Streja E; Ahluwalia A
Drugs; 2022 Jan; 82(1):43-54. PubMed ID: 34914085
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
[TBL] [Abstract][Full Text] [Related]
8. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
9. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
10. Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients.
Baslilar S; Saylan B
Ann Saudi Med; 2021; 41(5):268-273. PubMed ID: 34618609
[TBL] [Abstract][Full Text] [Related]
11. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
Tomasoni D; Inciardi RM; Lombardi CM; Tedino C; Agostoni P; Ameri P; Barbieri L; Bellasi A; Camporotondo R; Canale C; Carubelli V; Carugo S; Catagnano F; Dalla Vecchia LA; Danzi GB; Di Pasquale M; Gaudenzi M; Giovinazzo S; Gnecchi M; Iorio A; La Rovere MT; Leonardi S; Maccagni G; Mapelli M; Margonato D; Merlo M; Monzo L; Mortara A; Nuzzi V; Piepoli M; Porto I; Pozzi A; Sarullo F; Sinagra G; Volterrani M; Zaccone G; Guazzi M; Senni M; Metra M
Eur J Heart Fail; 2020 Dec; 22(12):2238-2247. PubMed ID: 33179839
[TBL] [Abstract][Full Text] [Related]
12. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
13. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
[TBL] [Abstract][Full Text] [Related]
14. Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19.
Xiang D; Ren X; Chen Q; Yu H; Li X; Liu D
Clin Exp Hypertens; 2021 May; 43(4):305-310. PubMed ID: 33356606
[No Abstract] [Full Text] [Related]
15. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry.
Uribarri A; Núñez-Gil IJ; Aparisi A; Becerra-Muñoz VM; Feltes G; Trabattoni D; Fernández-Rozas I; Viana-Llamas MC; Pepe M; Cerrato E; Capel-Astrua T; Romero R; Castro-Mejía AF; El-Battrawy I; López-País J; D'Ascenzo F; Fabregat-Andres O; Bardají A; Raposeiras-Roubin S; Marín F; Fernández-Ortiz A; Macaya C; Estrada V;
J Nephrol; 2020 Aug; 33(4):737-745. PubMed ID: 32602006
[TBL] [Abstract][Full Text] [Related]
16. Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19.
Negreira-Caamaño M; Piqueras-Flores J; Martínez-DelRio J; Nieto-Sandoval-Martin-DeLaSierra P; Aguila-Gordo D; Mateo-Gomez C; Salas-Bravo D; Rodriguez-Martinez M; Negreira-Caamaño M
High Blood Press Cardiovasc Prev; 2020 Dec; 27(6):561-568. PubMed ID: 32949380
[TBL] [Abstract][Full Text] [Related]
17. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
18. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
[TBL] [Abstract][Full Text] [Related]
19. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry.
Bertaina M; Nuñez-Gil IJ; Franchin L; Fernández Rozas I; Arroyo-Espliguero R; Viana-Llamas MC; Romero R; Maroun Eid C; Uribarri A; Becerra-Muñoz VM; Huang J; Alfonso E; Marmol-Mosquera F; Ugo F; Cerrato E; Fernandez-Presa L; Raposeiras Roubin S; Feltes Guzman G; Gonzalez A; Abumayyaleh M; Fernandez-Ortiz A; Macaya C; Estrada V;
Emerg Med J; 2021 May; 38(5):359-365. PubMed ID: 33727235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
